Clinical Trial

An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-02-24; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2026-06-11
Status change: Not Yet Recruiting → Recruiting 2024-07-18
Trial Details
NCT Number NCT06288230
Lead Sponsor Lantu Biopharma
Conditions Spinal Muscular Atrophy
Enrollment 20 participants
Start Date 2024-10-20
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15